These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 17620745

  • 1. The economics of effective AIDS treatment in Thailand.
    Over M, Revenga A, Masaki E, Peerapatanapokin W, Gold J, Tangcharoensathien V, Thanprasertsuk S.
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [Abstract] [Full Text] [Related]

  • 2. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E, Saba J, Muyingo S, Kahn JG.
    AIDS; 2006 Apr 04; 20(6):907-14. PubMed ID: 16549976
    [Abstract] [Full Text] [Related]

  • 3. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand.
    Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, Suebsaeng L, Lo YR.
    Southeast Asian J Trop Med Public Health; 2006 Jul 04; 37(4):704-15. PubMed ID: 17121296
    [Abstract] [Full Text] [Related]

  • 4. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S, Antunes OA, Fortunak JM.
    Antiviral Res; 2008 Sep 04; 79(3):143-65. PubMed ID: 18571246
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
    Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, Gompels M, Kinghorn G, McCarron B, Pozniak A, Tang A, Walsh J, Williams I, Gazzard B.
    Int J STD AIDS; 2008 May 04; 19(5):297-304. PubMed ID: 18482958
    [Abstract] [Full Text] [Related]

  • 7. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, Sanders R, Scotton CR, Soorapanth S, Boily MC, Garnett GP, McElroy PD.
    AIDS; 2008 Sep 12; 22(14):1829-39. PubMed ID: 18753932
    [Abstract] [Full Text] [Related]

  • 8. Assessing efficiency and costs of scaling up HIV treatment.
    Cleary SM, McIntyre D, Boulle AM.
    AIDS; 2008 Jul 12; 22 Suppl 1():S35-42. PubMed ID: 18664951
    [Abstract] [Full Text] [Related]

  • 9. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W, König HH, Schmidt JO, Kalk A.
    Trop Med Int Health; 2008 Oct 12; 13(10):1245-56. PubMed ID: 18721185
    [Abstract] [Full Text] [Related]

  • 10. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options.
    Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, Hira S, Nagelkerke N, Rao AS, Heywood P.
    Sex Transm Dis; 2006 Oct 12; 33(10 Suppl):S145-52. PubMed ID: 17003679
    [Abstract] [Full Text] [Related]

  • 11. Combining prevention, treatment and care: lessons from South Africa.
    Achmat Z, Simcock J.
    AIDS; 2007 Jul 12; 21 Suppl 4():S11-20. PubMed ID: 17620746
    [Abstract] [Full Text] [Related]

  • 12. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
    Simpson KN, Baran RW, Kirbach SE, Dietz B.
    Value Health; 2011 Dec 12; 14(8):1048-54. PubMed ID: 22152173
    [Abstract] [Full Text] [Related]

  • 13. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK, Simpson KN.
    Value Health; 2000 Dec 12; 3(3):186-201. PubMed ID: 16464183
    [Abstract] [Full Text] [Related]

  • 14. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y.
    J Antimicrob Chemother; 2004 Apr 12; 53(4):558-61. PubMed ID: 14985277
    [Abstract] [Full Text] [Related]

  • 15. The (political) economics of antiretroviral treatment in developing countries.
    Nattrass NJ.
    Trends Microbiol; 2008 Dec 12; 16(12):574-9. PubMed ID: 18964022
    [Abstract] [Full Text] [Related]

  • 16. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
    Renaud-Théry F, Nguimfack BD, Vitoria M, Lee E, Graaff P, Samb B, Perriëns J.
    AIDS; 2007 Jul 12; 21 Suppl 4():S89-95. PubMed ID: 17620758
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.